Anemia management of adult hemodialysis patients in the U.S.: Results from the 1997 ESRD Core Indicators Project

Kidney International

Volumn 57, Issue 2, 2000, Pages 578-589

  Frankenfield, Diane L ^a,b,c,d,e,f   Johnson, Curtis A ^a,b,c,d,e,f   Wish, Jay B ^a,b,c,d,e,f   Rocco, Michael V ^a,b,c,d,e,f   Madore, Francois ^a,b,c,d,e,f   Owen Jr , William F ^a,b,c,d,e,f  

^a CENTERS FOR MEDICARE AND MEDICAID SERVICES   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Dialysis; End stage renal disease; Erythropoietin; Hematocrit; Iron; Serum ferritin; Transferrin

Indexed keywords

FERRITIN; IRON DERIVATIVE; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TRANSFERRIN BLOOD LEVEL; TREATMENT OUTCOME; UNITED STATES;

EID: 0033933041     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00878.x     Document Type: Article

References (43)

1. 1. MADORE F, BRIDGES K, LEW N, LOWRIE E, LAZARUS JM, OWEN WF: Anemia in hemodialysis patients: Variables impacting this outcome predictor. J Am Soc Nephrol 8:1921-1929, 1997
2. 2. MA J, EBBEN J, HONG X, COLLINS A: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
3. 3. NKF-DOQI: Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. New York, National Kidney Foundation, 1997
4. 4. HEALTH CARE FINANCING ADMINISTRATION: 1997 Annual Report End Stage Renal Disease. Baltimore, ESRD, Core Indicators Project. Department of Health, Human Services, Health Care Financing Administration Office of Clinical Standards, Quality, December 1997
5. 5. HELGERSON SD, MCCLELLAN WM, FREDERICK RP, BEAVER SK, FRANKENFIELD DL, MCMULLAN M: Improvement in adequacy of delivered dialysis for adult in-center hemodialysis patients in the United States 1993-1995. Am J Kidney Dis 29:851-861, 1997
6. 6. US RENAL DATA SYSTEM: USRDS 1997 Annual Data Report. Bethesda, National Institutes of Health National Institute of Diabetes, Digestive, Kidney Diseases, April 1997
7. 7. COTTER DJ, THAMER M, KIMMEL PL, SADLER JH: Secular trends in recombinant erythropoietin therapy among the US hemodialysis population: 1990-1996. Kidney Int 54:2129-2139, 1998
8. 8. YOUNG EW, BLOEMBERGEN WE, WOODS JD, EMMERT G, PORT FK, WOLFE RA, JONES CA, HELD PJ: Dialysis dose, membrane type, and anemia control. Am Kidney Dis 32(Suppl 4):S157-S160, 1998
9. 9. US RENAL DATA SYSTEM: The USRDS Dialysis Morbidity and Mortality Study (Wave 1). Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, U. S. Renal Data System, 1996 Annual Data Report 4, 1996
10. 10. FRANKENFIELD D, MCCLELLAN WM, HELGERSON S, LOWRIE EG, ROCCO M, OWEN WF: Relationship between urea reduction ratio, demographic characteristics, and body weight for patients in the 1996 National ESRD Core Indicators Project. Am J Kidney Dis 33:584-591, 1999
11. 11. DAUGIRDAS JT: Second generation logarithmic estimates of single-pool variable Kt/V: An analysis of error. J Am Soc Nephrol 4:1205-1213, 1993
12. 12. HEALTH CARE FINANCING ADMINISTRATION: ESRD Core Indicators Project Special Report #A. Results of Validation Study: Comparison of Data Abstracted by ESRD Facility Staff and by ESRD Network Staff, Baltimore, Department of Health and Human Services, Health Care Financing Administration, Office of Clinical Standards and Quality, 1997
13. 13. DEAN JA, BURTON AH, COULOMBIER D, BRENDEL KA, SMITH DC, BURTON AH, DICKER RC, SULLIVAN K, FAGAN RF, ARMER TG: Epi Info Version 6.04a: A Word Processing Database and Statistics Program for Epidemiology on Microcomputers. Atlanta, Centers for Disease Control and Prevention, 1996
14. 14. NORUSIS MJ: SPSS, for Windows Advanced Statistics, Release 6.1. Chicago, 1993
15. 15. KALTWASSER JP, GOTTSCHALK R: Erythropoietin and iron. Kidney Int 55:S49-S56, 1999
16. 16. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWE JK, ADAMSON JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase 1 and 2 clinical trial. N Engl J Med 316:73-78, 1987
17. 17. IFUDU O, FELDMAN J, FRIEDMAN EA: The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334:420-425, 1996
18. 18. OWEN WF, LOWRIE EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54:627-636, 1998
19. 19. KALANTAR-ZADEH K, HOFFKEN B, WUNSCH H, FINK H, KLEINER M, LUFT FC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26:292-299, 1995
20. 20. FISHBANE S, KOWALSKI EA, IMBRANO LJ, MAESAKA JK: The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7:2654-2657, 1996
21. 21. FISHBANE S, FREIG L, MAESAKA J: Reduction in recombinant erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
22. 22. SILVERBERG DS, IAINA A, PEER G, KAPLAN E, LEVI BA, FRANK N, STEINBRUCH S, BLUM M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
23. 23. WINGARD RL, PARKER RA, ISMAIL N, HAKIM RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 25:433-439, 1995
24. 24. MARKOWITZ GS, KAHN GA, FEINGOLD RE, COCO M, LYNN RI: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48:34-40, 1997
25. 25. NISSENSON AR: Achieving target hematocrit in dialysis patients: New concepts in iron management. Am J Kidney Dis 30:907-911, 1997
26. 26. ST. PETER WL, LAMBRACHT LJ, MACRES M: Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28:523-528, 1996
27. 27. FISHBANE S, UNGUREANU VD, MAESAKA JK, KAUPKE CJ, LIM V, WISH J: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534, 1996
28. 28. HOEN B, PAUL-DAUPHIN A, HESTIN D, KESSLER M: EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. Am J Nephrol 9:869-876, 1998
29. 29. ESCHBACH JW, ADAMSON JW: Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy. Kidney Int 55:S35-S43, 1998
30. 30. FISHBANE S, MITTAL SK, MAESAKA JK: Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int 55:S67-S70, 1999
31. 31. PERRY G, BYERS T, YIP R, MARGEN S: Iron nutrition does not account for the hemoglobin differences between blacks and whites. J Nutr 122:1417-1424, 1992
32. 32. MEYERS L, HABICHT J, JOHNSON C: Components of the differences in hemoglobin concentration in blood between black and white women in the United States. Am J Epidemiol 109:539-549, 1979
33. 33. ROCCO MV, BURKART JM: Prevalence of missed treatments and early sign-offs in hemodialysis patients. J Am Soc Nephrol 4:1178-1183, 1993
34. 34. OBRADOR GT, PEREIRA BJ: Early referral to the nephrologist and timely initiation of renal replacement therapy: A paradigm shift in management of patients with chronic renal failure. Am J Kidney Dis 31:398-417, 1998
35. 35. IFUDU O, DAWOOD M, FRIEDMAN EA: Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure. Nephron 77:315-318, 1997
36. 36. COHEN D, RAJA DM: Erythropoietin (EPO) requirements remain high in EPO resistant patients after iron repletion. ASAIO J 44:M596-M597, 1998
37. 37. ARGILES A, MOURAD G, LORHO R, KERR PG, FLAVIER JL, CANAUD B, MION CM: Medical treatment of severe hyperparathyroidism and its influence on anemia in end-stage renal failure. Nephrol Dial Transplant 9:1809-1812, 1994
38. 38. RAULT R, MAGNONE M: The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis. ASAIO J 42:M901-M903, 1996
39. 39. DONNELLY SM, ALI MA, CHURCHILL DN: Bioavailability of iron in hemodialysis patients treated with erythropoietin: Evidence for the inhibitory role of aluminum. Am J Kidney Dis 16:447-451, 1990
40. 40. GRUTZMACHER P, EHMER B, LIMBACH J, MESSINGER D, KULBE KD, SCIGALLA P: Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism. Blood Purif 8:279-284, 1990
41. 41. ESCHBACH JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35:134-148, 1989
42. 42. WISH J, ROBERTS J, BESARAB A, OWEN WF: Cost-effectiveness of the DOQI clinical practice guidelines. Adv Ren Replace Ther 6:67-74, 1999
43. 43. PARK L, UHTHOFF T, TIERNEY M, NADLER S: Effect of intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 31:835-840, 1998